Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Upstream BioUPB -3.04%10 Market Cap is $380.40 Mil as of Jul. 17, 2026. GuruFocus rates UPB with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 1,423 Biotechnology companies, Upstream Bio ranks better than 67.96% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Upstream Bio's share price for the quarter that ended in Mar. 2026 was $9. Upstream Bio's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 54.42 Mil. Therefore, Upstream Bio's market cap for the quarter that ended in Mar. 2026 was $489.78 Mil.
Upstream Bio's quarterly market cap
increased
from Sep. 2025 ($1,015.74 Mil) to Dec. 2025 ($1,472.56 Mil) but then
declined
from Dec. 2025 ($1,472.56 Mil) to Mar. 2026 ($489.78 Mil).
Upstream Bio's annual market cap
increased
from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($881.23 Mil) and
increased
from Dec. 2024 ($881.23 Mil) to Dec. 2025 ($1,472.56 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Upstream Bio's Enterprise Value for Today is $88.02 Mil.
Upstream Bio (NAS:UPB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Upstream Bio Market Cap Related Terms
Upstream Bio Market Cap Historical Data
* Premium members only.
The historical data trend for Upstream Bio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Upstream Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Upstream Bio Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Upstream Bio's Market Cap distribution charts can be found below:
* The bar in red indicates where Upstream Bio's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Upstream Bio's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Upstream Bio (UPB) has a Market Cap of $380.40 Mil as of Jul. 17, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Upstream Bio and its competitors. According to the industry distribution chart, Upstream Bio ranks #456 out of 1423 companies in the Biotechnology industry, placing it in the top 32%.
Is Upstream Bio's Market Cap too high?
Upstream Bio's current Market Cap is $380.40 Mil. The Biotechnology industry median Market Cap is 113.78. Upstream Bio's value of $380.40 Mil is 234.3% above this industry median. Based on the distribution chart, Upstream Bio ranks #456 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Upstream Bio has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Upstream Bio's Market Cap compare to OABI and VNDA?
According to the Biotechnology industry distribution chart, Upstream Bio ranks #456 out of 1423 companies for Market Cap. This puts Upstream Bio in the upper half of its industry. The industry median Market Cap is 113.78. Upstream Bio's value of $380.40 Mil is 234.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.78, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Upstream Bio's current Market Cap of $380.40 Mil is 234.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Upstream Bio and its competitors. For the Biotechnology industry, the median Market Cap is 113.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Upstream Bio's current Market Cap is $380.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Upstream Bio stock overvalued right now?
Upstream Bio (UPB) has a current Market Cap of $380.40 Mil. The current Market Cap is $380.40 Mil and 234.3% above the Biotechnology industry median of 113.78. Upstream Bio's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Upstream Bio (UPB), the current Market Cap is $380.40 Mil as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
10GF Score
Get the complete analysis for UPB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPB has been successfully added to your 
